Latest News
EQT Life Sciences exits Vivasure Medical in EUR185m sale to Haemonetics
12 January 2026 - EQT Life Sciences, a part of Swedish private equity company EQT AB (STO: EQT), announced on Monday that it has exited Vivasure Medical Limited, an Ireland-based developer of percutaneous vessel closure technology, through a sale to ...
GRIN Therapeutics doses first patient in global Phase 3 trial of investigational radiprodil for GRIN-NDD
12 January 2026 - GRIN Therapeutics Inc, a developer of precision therapeutics for neurodevelopmental disorders, announced on Friday that it has dosed the first patient in its global Phase 3 Beeline trial of investigational radiprodil in individuals ...
Phanes Therapeutics reports clinical data on spevatamig chemotherapy combination in frontline treatment of mPDAC
12 January 2026 - Phanes Therapeutics Inc, a California-based clinical stage biotech company focused on innovative drug discovery and development in oncology, on Friday reported the first clinical data evaluating spevatamig in combination with chemot...
Clover Biopharmaceuticals enrols first participants in Phase 2 trial of respiratory combination vaccine candidates
12 January 2026 - Clover Biopharmaceuticals Ltd (HKEX:02197), a China-based commercial-stage biotechnology company, announced on Monday that the first participants have been enrolled in a Phase 2 clinical trial of SCB-1022 (RSV + hMPV) and SCB-1033 (...
FDA accepts NDA resubmission for Camurus' acromegaly drug Oclaiz
9 January 2026 - Swedish biopharmaceutical company Camurus (STO: CAMX), which develops long-acting medicines for severe and chronic diseases, said on Friday that the US Food and Drug Administration (FDA) has accepted for review its resubmitted New Dr...